GS-100 ta un rekombinant AAV9 vector ku ta kodia e gen NGLY1 humano. E ta un droga orfo di e US Food and Drug Administration i e European Medicine Agency (EMA). E terapia tambe a haña e FDA's rare pediatric disease designation na 2021 i fast track designation aña pasá.